JP2019526268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526268A5 JP2019526268A5 JP2019512872A JP2019512872A JP2019526268A5 JP 2019526268 A5 JP2019526268 A5 JP 2019526268A5 JP 2019512872 A JP2019512872 A JP 2019512872A JP 2019512872 A JP2019512872 A JP 2019512872A JP 2019526268 A5 JP2019526268 A5 JP 2019526268A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- polypeptide
- items
- active fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 141
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 131
- 229920001184 polypeptide Polymers 0.000 claims description 130
- 210000004027 cell Anatomy 0.000 claims description 90
- 239000012634 fragment Substances 0.000 claims description 67
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 55
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 49
- 102000040430 polynucleotide Human genes 0.000 claims description 34
- 108091033319 polynucleotide Proteins 0.000 claims description 34
- 239000002157 polynucleotide Substances 0.000 claims description 34
- 238000006467 substitution reaction Methods 0.000 claims description 25
- 102220631830 AH receptor-interacting protein_E42R_mutation Human genes 0.000 claims description 23
- 102200130585 rs778210210 Human genes 0.000 claims description 22
- 102220543096 Protein pitchfork_T48V_mutation Human genes 0.000 claims description 19
- 102220028518 rs199469669 Human genes 0.000 claims description 16
- 102220570141 Pyridoxal-dependent decarboxylase domain-containing protein 1_S40H_mutation Human genes 0.000 claims description 14
- 102220499955 Testis-specific Y-encoded-like protein 4_R30L_mutation Human genes 0.000 claims description 14
- 102220541155 Tumor necrosis factor receptor superfamily member 5_S35G_mutation Human genes 0.000 claims description 14
- 102220559237 Voltage-dependent L-type calcium channel subunit alpha-1C_N32R_mutation Human genes 0.000 claims description 14
- 102200012954 rs121918642 Human genes 0.000 claims description 14
- 102220285812 rs905812561 Human genes 0.000 claims description 14
- 102000006306 Antigen Receptors Human genes 0.000 claims description 13
- 108010083359 Antigen Receptors Proteins 0.000 claims description 13
- 230000004568 DNA-binding Effects 0.000 claims description 13
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 12
- 102200104655 rs11555566 Human genes 0.000 claims description 12
- 102220011641 rs201315884 Human genes 0.000 claims description 12
- 102220645026 Manganese-dependent ADP-ribose/CDP-alcohol diphosphatase_V68I_mutation Human genes 0.000 claims description 10
- 102220215046 rs764941621 Human genes 0.000 claims description 10
- 102220352322 c.232A>C Human genes 0.000 claims description 8
- 102220512398 Aprataxin and PNK-like factor_I100V_mutation Human genes 0.000 claims description 6
- 102220474067 Protection of telomeres protein 1_S72D_mutation Human genes 0.000 claims description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102220294507 rs373781844 Human genes 0.000 claims description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 6
- 108060002716 Exonuclease Proteins 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 102000013165 exonuclease Human genes 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102200057181 rs1064793683 Human genes 0.000 claims description 4
- 102220029238 rs72554332 Human genes 0.000 claims description 4
- 102000004533 Endonucleases Human genes 0.000 claims description 3
- 108010042407 Endonucleases Proteins 0.000 claims description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 239000012642 immune effector Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 102220267892 rs1555193020 Human genes 0.000 claims description 3
- 102000048362 human PDCD1 Human genes 0.000 claims description 2
- 102220281712 rs777988634 Human genes 0.000 claims 7
- 102220157833 rs61752864 Human genes 0.000 claims 5
- 208000002925 dental caries Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 52
- 230000001506 immunosuppresive effect Effects 0.000 description 28
- 239000003623 enhancer Substances 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 102220536706 Hemoglobin subunit epsilon_K34R_mutation Human genes 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 9
- 102220485790 Destrin_S40R_mutation Human genes 0.000 description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 8
- 230000005782 double-strand break Effects 0.000 description 8
- 102220222867 rs1060500282 Human genes 0.000 description 8
- 102200081901 rs137854510 Human genes 0.000 description 8
- 102220307145 rs1556367745 Human genes 0.000 description 8
- 102220088279 rs869025249 Human genes 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 108010002586 Interleukin-7 Proteins 0.000 description 6
- 102220645900 Protein pitchfork_T48R_mutation Human genes 0.000 description 6
- 102220611719 RNA polymerase I-specific transcription initiation factor RRN3_R28E_mutation Human genes 0.000 description 6
- 102220261986 rs1044174795 Human genes 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 102220040900 rs587778522 Human genes 0.000 description 5
- 102220195966 rs745387614 Human genes 0.000 description 5
- -1 CD8α Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 4
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 4
- 102100037935 Polyubiquitin-C Human genes 0.000 description 4
- 102000009572 RNA Polymerase II Human genes 0.000 description 4
- 108010009460 RNA Polymerase II Proteins 0.000 description 4
- 108010056354 Ubiquitin C Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 102220570273 Protein HID1_S72I_mutation Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 108010031676 Kynureninase Proteins 0.000 description 2
- 102220526321 NHP2-like protein 1_G38K_mutation Human genes 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 102220478507 Vacuolar protein sorting-associated protein 35_T82R_mutation Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 102220349640 c.88C>A Human genes 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 102000005447 kynureninase Human genes 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102200044888 rs121913412 Human genes 0.000 description 2
- 102200012974 rs121918641 Human genes 0.000 description 2
- 102220011282 rs312262813 Human genes 0.000 description 2
- 102220005162 rs33945705 Human genes 0.000 description 2
- 102200029472 rs587781918 Human genes 0.000 description 2
- 102220282920 rs753009349 Human genes 0.000 description 2
- 102220151657 rs763546006 Human genes 0.000 description 2
- 102220319624 rs766454930 Human genes 0.000 description 2
- 102220021200 rs80356967 Human genes 0.000 description 2
- 102200010049 rs869025189 Human genes 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100162704 Emericella nidulans I-AniI gene Proteins 0.000 description 1
- 108090000652 Flap endonucleases Proteins 0.000 description 1
- 102000004150 Flap endonucleases Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102220630183 Immunoglobulin alpha-2 heavy chain_A76S_mutation Human genes 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023119149A JP7538301B2 (ja) | 2016-09-08 | 2023-07-21 | Ｐｄ－１ホーミングエンドヌクレアーゼバリアント、組成物、および使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385079P | 2016-09-08 | 2016-09-08 | |
| US62/385,079 | 2016-09-08 | ||
| US201662414279P | 2016-10-28 | 2016-10-28 | |
| US62/414,279 | 2016-10-28 | ||
| PCT/US2017/050774 WO2018049226A1 (en) | 2016-09-08 | 2017-09-08 | Pd-1 homing endonuclease variants, compositions, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023119149A Division JP7538301B2 (ja) | 2016-09-08 | 2023-07-21 | Ｐｄ－１ホーミングエンドヌクレアーゼバリアント、組成物、および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526268A JP2019526268A (ja) | 2019-09-19 |
| JP2019526268A5 true JP2019526268A5 (https=) | 2020-10-15 |
| JP7356346B2 JP7356346B2 (ja) | 2023-10-04 |
Family
ID=61562250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512872A Active JP7356346B2 (ja) | 2016-09-08 | 2017-09-08 | Ｐｄ－１ホーミングエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2023119149A Active JP7538301B2 (ja) | 2016-09-08 | 2023-07-21 | Ｐｄ－１ホーミングエンドヌクレアーゼバリアント、組成物、および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023119149A Active JP7538301B2 (ja) | 2016-09-08 | 2023-07-21 | Ｐｄ－１ホーミングエンドヌクレアーゼバリアント、組成物、および使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11365226B2 (https=) |
| EP (2) | EP3510157B1 (https=) |
| JP (2) | JP7356346B2 (https=) |
| KR (2) | KR102622910B1 (https=) |
| CN (1) | CN109923211A (https=) |
| AU (1) | AU2017323629B9 (https=) |
| BR (1) | BR112019004629A2 (https=) |
| CA (1) | CA3035455A1 (https=) |
| DK (1) | DK3510157T5 (https=) |
| ES (1) | ES2952525T3 (https=) |
| IL (1) | IL265045B2 (https=) |
| MA (1) | MA46389A (https=) |
| MX (1) | MX2019002725A (https=) |
| NZ (1) | NZ751189A (https=) |
| SG (1) | SG11201901757YA (https=) |
| WO (1) | WO2018049226A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| KR102622910B1 (ko) | 2016-09-08 | 2024-01-10 | 2세븐티 바이오, 인코포레이티드 | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 |
| US11530395B2 (en) | 2016-10-17 | 2022-12-20 | 2Seventy Bio, Inc. | TGFBetaR2 endonuclease variants, compositions, and methods of use |
| CA3041517A1 (en) | 2016-10-19 | 2018-04-26 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| AU2018221730B2 (en) | 2017-02-15 | 2024-06-20 | Novo Nordisk A/S | Donor repair templates multiplex genome editing |
| IL313037A (en) | 2017-05-25 | 2024-07-01 | 2Seventy Bio Inc | Cblb endonuclease variants, compositions, and methods of use |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CN112543766A (zh) | 2018-04-03 | 2021-03-23 | 斯特里迪比奥公司 | 抗体逃避性病毒载体 |
| CA3094465A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| US20210363191A1 (en) | 2018-04-03 | 2021-11-25 | Stridebio, Inc. | Antibody-evading virus vectors |
| EP3820487A4 (en) * | 2018-05-14 | 2022-03-09 | Themba Inc. | Gene editing for autoimmune disorders |
| WO2020072059A1 (en) * | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| US12577547B2 (en) * | 2018-12-10 | 2026-03-17 | Regeneron Pharmaceuticals, Inc. | PDCD-1 homing endonuclease variants |
| WO2020123371A2 (en) * | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Homing endonuclease variants |
| CN113840920A (zh) * | 2019-03-14 | 2021-12-24 | 加利福尼亚大学董事会 | 合并的敲入筛选和在内源基因座控制下共表达的异源多肽 |
| BR112021018776A2 (pt) | 2019-03-21 | 2021-11-30 | Stridebio Inc | Vetores de vírus adenoassociado recombinante |
| CN114555788A (zh) * | 2019-09-06 | 2022-05-27 | 阿维塔斯有限公司 | 免疫细胞工程化用于体外细胞治疗 |
| US20220364091A1 (en) * | 2019-10-09 | 2022-11-17 | The Regents Of The University Of California | Compositions and methods for reprogramming age-restricted non-neuronal cells |
| KR20220083714A (ko) | 2019-10-17 | 2022-06-20 | 스트라이드바이오 인코포레이티드 | 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터 |
| EP4200408A1 (en) | 2020-08-19 | 2023-06-28 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of rett syndrome |
| TW202242124A (zh) * | 2021-01-14 | 2022-11-01 | 美商史崔德生物公司 | 靶向ｔ細胞之ａａｖ載體 |
| US20240218351A1 (en) | 2021-06-14 | 2024-07-04 | 2Seventy Bio, Inc. | Single stranded rna purification methods |
| US20250249096A1 (en) * | 2021-10-19 | 2025-08-07 | Peter Maccallum Cancer Institute | Compositions and Methods for Immunotherapy |
| AU2024259472A1 (en) * | 2023-04-20 | 2025-11-13 | Peter Maccallum Cancer Institute | Compositions and methods for immunotherapy - ii |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| JP3257675B2 (ja) | 1990-10-12 | 2002-02-18 | マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． | 修飾リボザイム |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| NZ522840A (en) | 2000-06-01 | 2004-12-24 | Univ North Carolina | A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together |
| ATE452972T1 (de) | 2001-05-01 | 2010-01-15 | Ca Nat Research Council | Induzierbares expressionssystem in eukaryotischen zellen |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| WO2007049095A1 (en) | 2005-10-25 | 2007-05-03 | Cellectis | Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof |
| AU2007347328B2 (en) | 2007-02-19 | 2013-03-07 | Cellectis | LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| CA2700231C (en) | 2007-09-27 | 2018-09-18 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| ES2683695T3 (es) | 2010-01-12 | 2018-09-27 | The University Of North Carolina At Chapel Hill | Repeticiones terminales invertidas restrictivas para vectores virales |
| CA2788682C (en) | 2010-02-05 | 2019-03-05 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| US20110256607A1 (en) | 2010-04-16 | 2011-10-20 | Georg Hausner | Homing endonucleases |
| US20140148361A1 (en) | 2010-06-07 | 2014-05-29 | Barry L. Stoddard | Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof |
| EP2633040B1 (en) | 2010-10-27 | 2019-07-10 | Cellectis | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| WO2012118717A2 (en) | 2011-02-28 | 2012-09-07 | Seattle Children's Research Institute | Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| RU2650811C2 (ru) * | 2012-02-24 | 2018-04-17 | Фред Хатчинсон Кэнсер Рисерч Сентер | Композиции и способы лечения гемоглобинопатии |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| US20140015679A1 (en) | 2012-07-15 | 2014-01-16 | Green Badge LLC | Specialty Plant Moisture Sensing |
| DE112012007250B4 (de) | 2012-12-20 | 2024-10-24 | Mitsubishi Electric Corp. | Fahrzeuginterne Vorrichtung und Programm |
| MX2015015638A (es) | 2013-05-13 | 2016-10-28 | Cellectis | Metodos para diseñar celulas t altamente activas para inmunoterapia. |
| JP6488283B2 (ja) | 2013-05-31 | 2019-03-20 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃ−ｃケモカイン受容体５型（ｃｃｒ５）遺伝子を開裂するｌａｇｌｉｄａｄｇホーミングエンドヌクレアーゼおよびその用途 |
| US10000746B2 (en) * | 2013-05-31 | 2018-06-19 | Cellectis | LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof |
| WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MX2018010924A (es) | 2016-03-11 | 2019-02-13 | Bluebird Bio Inc | Células efectoras inmunitarias con edición genómica. |
| CN109415687A (zh) | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| JP2019525759A (ja) | 2016-07-25 | 2019-09-12 | ブルーバード バイオ， インコーポレイテッド | Ｂｃｌ１１ａホーミングエンドヌクレアーゼバリアント、組成物、および使用方法 |
| WO2018035141A1 (en) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
| MA46018A (fr) | 2016-08-19 | 2019-06-26 | Bluebird Bio Inc | Activateurs d'édition du génome |
| WO2018039333A1 (en) | 2016-08-23 | 2018-03-01 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| KR102622910B1 (ko) | 2016-09-08 | 2024-01-10 | 2세븐티 바이오, 인코포레이티드 | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 |
| WO2018071565A1 (en) | 2016-10-11 | 2018-04-19 | Bluebird Bio, Inc. | TCRa HOMING ENDONUCLEASE VARIANTS |
| US11530395B2 (en) | 2016-10-17 | 2022-12-20 | 2Seventy Bio, Inc. | TGFBetaR2 endonuclease variants, compositions, and methods of use |
| CN106749666B (zh) | 2016-12-22 | 2018-12-25 | 福州大学 | 一种人源程序性死亡受体hPD-1单克隆抗体 |
| CN106939049B (zh) | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| IL313037A (en) | 2017-05-25 | 2024-07-01 | 2Seventy Bio Inc | Cblb endonuclease variants, compositions, and methods of use |
| WO2019070974A1 (en) | 2017-10-04 | 2019-04-11 | Bluebird Bio, Inc. | PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| US12577547B2 (en) | 2018-12-10 | 2026-03-17 | Regeneron Pharmaceuticals, Inc. | PDCD-1 homing endonuclease variants |
-
2017
- 2017-09-08 KR KR1020227034173A patent/KR102622910B1/ko active Active
- 2017-09-08 AU AU2017323629A patent/AU2017323629B9/en active Active
- 2017-09-08 MX MX2019002725A patent/MX2019002725A/es unknown
- 2017-09-08 SG SG11201901757YA patent/SG11201901757YA/en unknown
- 2017-09-08 KR KR1020197009497A patent/KR102451510B1/ko active Active
- 2017-09-08 US US16/330,039 patent/US11365226B2/en active Active
- 2017-09-08 JP JP2019512872A patent/JP7356346B2/ja active Active
- 2017-09-08 EP EP17849655.0A patent/EP3510157B1/en active Active
- 2017-09-08 MA MA046389A patent/MA46389A/fr unknown
- 2017-09-08 CA CA3035455A patent/CA3035455A1/en active Pending
- 2017-09-08 ES ES17849655T patent/ES2952525T3/es active Active
- 2017-09-08 IL IL265045A patent/IL265045B2/en unknown
- 2017-09-08 BR BR112019004629-1A patent/BR112019004629A2/pt active Search and Examination
- 2017-09-08 WO PCT/US2017/050774 patent/WO2018049226A1/en not_active Ceased
- 2017-09-08 NZ NZ751189A patent/NZ751189A/en unknown
- 2017-09-08 CN CN201780065641.7A patent/CN109923211A/zh active Pending
- 2017-09-08 EP EP23173344.5A patent/EP4248979A3/en active Pending
- 2017-09-08 DK DK17849655.0T patent/DK3510157T5/da active
-
2022
- 2022-05-06 US US17/738,484 patent/US11912746B2/en active Active
-
2023
- 2023-07-21 JP JP2023119149A patent/JP7538301B2/ja active Active
-
2024
- 2024-02-22 US US18/584,363 patent/US12391734B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526268A5 (https=) | ||
| JP2020521456A5 (https=) | ||
| JP2019535240A5 (https=) | ||
| JP2021520202A5 (https=) | ||
| JP7649258B2 (ja) | 癌を治療するための組成物および方法 | |
| WO2019089884A2 (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
| JP7431735B2 (ja) | Ｄａｒｉｃインターロイキン受容体 | |
| CA3032838A1 (en) | Compositions and methods for immunotherapy | |
| CN114616248A (zh) | 二聚化剂调节的免疫受体复合物 | |
| CN113412276A (zh) | 二聚化剂调节的免疫受体复合物 | |
| KR20200108285A (ko) | Nkg2d daric 수용체 | |
| KR20220031549A (ko) | Cll-1 표적화 면역요법 | |
| Stärck et al. | Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell–derived T cells | |
| EP3707258A1 (en) | Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy | |
| JP2025061188A (ja) | キメラサイトカイン受容体 | |
| KR20220031554A (ko) | Cd33 표적화 면역요법 | |
| US20250333762A1 (en) | Cell-specific transcriptional regulatory sequences and uses thereof | |
| EP1450611A2 (en) | Method for the generation of antigen-specific lymphocytes | |
| CN110819596A (zh) | 具有增强的迁移能力的修饰的细胞 | |
| US20250228940A1 (en) | Compositions and methods for efficient and stable genetic modification of eukaryotic cells | |
| RU2019110065A (ru) | Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1 | |
| RU2019141853A (ru) | Варианты, композиции и способы применения эндонуклеазы cblb | |
| Philip | RQR8: A universal safety switch for cellular therapies | |
| WO2025179057A1 (en) | In vivo modification of cell genomes | |
| CN115803438A (zh) | 用于cd3+细胞体外和体内表达基因治疗产物的启动子序列 |